Introduction
In most longitudinal studies in all areas of medicine and public health, missing values and dropout are common. For a variety of reasons, some patients do not complete their intended follow-up according to protocol, and they are often described as having "dropped out" before the conclusion of the trial. This situation generates missing values for the study.
Missing data have three important implications for longitudinal studies. First, the dataset becomes unbalanced over time, which complicates choosing the right methods of analyses. Second, because of this missingness, some unavoidable loss in information reduces the efficiency of the study. Finally, the missing values introduce bias that can cause misleading inferences.
The main problem that arises with missing data is that the distribution of the observed data may not be the same as the distribution of the complete data. Some missingness may be unrelated to the observed or unobserved responses, some may be related to the observed data, some related to the unobserved data, and some to both. Little and Rubin 1 classified the missing value mechanisms as missing completely at random (MCAR), missing at random (MAR), and not missing at random (NMAR). MCAR is a condition in which missing values are randomly distributed across all observations. MAR is a condition in which missing values are not randomly distributed across all observations but are randomly distributed within one or more subsamples. Under MCAR and MAR, the missing data mechanisms are often referred to as being "ignorable"; by contrast, the missing data mechanism NMAR is often referred to as "nonignorable. "
Intent-to-treat (ITT) analysis has become a widely accepted method for the analysis of controlled clinical trials. ITT analysis, as suggested by Schwartz and Lellouch, 2 is a pragmatic approach to avoid bias in estimating the effect of treatment assignment in randomized clinical trials. ITT analysis compares the study groups in terms of the treatment to which they were randomly allocated, regardless of protocol deviations and participant compliance or withdrawal. Missing values can lead to problems in identifying the ITT population, which makes the data analysis more complex and challenging. No adequate strategy exists for ITT analyses of longitudinal controlled clinical trial data with missing values.
In this report, we perform a detailed investigation of simulation studies to develop recommendations for ITT analysis of longitudinal controlled clinical trial data with missing values. We compare estimates, sizes (type I errors), and power among several popular ad hoc approaches and the general linear mixed model (GLMM) approach for different proportions of missing values. We also try to answer a fundamental question faced by researchers in the presence of missing values: which method or which combination of imputation and analysis methods will provide the maximum benefits in terms of size and power of the test for different proportion of missing values in a longitudinal design setting? More specifically, does the mixed model provide more powerful tests without inflating the sizes in all missing scenarios in longitudinal design settings?
Methods
Many methods have been proposed and developed over the past two decades to deal with missing values and dropout issues. In a review paper, Fitzmaurice 3 summarizes methods for handling dropouts into four categories, namely the complete-case analysis, available-case methods, model-based approaches, and imputation methods. Except for complete-case analysis, the categories are all general terms that refer to a large collection of techniques.
Complete-case analysis refers to the method used to analyze the data that include only the complete cases; it excludes the subjects with missing data. Completecase analysis, by definition, is not ITT analysis. By omitting all cases with missing values at any measurement occasion, this technique can result in a substantial loss of information, which has a negative impact on precision and power. Complete-case analysis is a valid method only when the dropouts are missing completely at random (MCAR). Fixed-value imputation methods substitute each missing or dropout value with a fixed value that is generated by one of the ad hoc strategies. One widely used ad hoc approach in clinical trial data analyses, which is "last observation carried forward" (LOCF), belongs to the fixed-value class of imputation methods. A simulation-based size and power comparison of various ad hoc strategies under different dropout mechanisms can be found in Unnebrink and Windeler. 5 LOCF is the most popular method for ad hoc imputations; it fills the missing values with the last available non-missing values of the same subject. Best-value replacement (BVR) and worst-value replacement (WVR) are the other two ad-hoc imputation methods widely used in medical research. In these methods, the missing values are filled in with the best or worst values from that subject. The selection of best or worst value replacement method depends on the scientific knowledge of the variable; in most situations, they are the subject's minimum and maximum values.
Multiple imputation methods impute the missing values using a set of sampled values based on models for the missing data conditional on all relevant observed data. Thus, the multiple imputation methods account for the underlying uncertainty. 6, 7 Little and Yau 8 applied multiple imputations in ITT analysis for longitudinal studies under several different assumptions and compared results with those from available-case methods.
In short, available methods to impute missing values are appropriate to use only under some assumptions about the missing data mechanism, and every method has drawbacks. All ad hoc methods require the MCAR assumption; maximum likelihood-based methods require either MCAR or MAR assumptions. If the missing values are NMAR, then standard methods of analysis are not valid and usually a sensitivity analysis is recommended.
The mixed model is the most important availablecase method. In it, covariates can be either time-invariant or time-varying. In addition, generalizations exist for non-normal data. The mixed model equation for the kth subject can be written as
with the assumptions that
Thus, the covariance matrix is
The model can be constructed using the "usual" linear model method E(Y k ) = X k β, where:
Y k = vector of all available measurements from the kth subject, through all periods of observation X k = fixed effects design matrix for the kth subject corresponding to the available measurements in Y k β = fixed-effect parameters matrix for all subjects Z k = random effects design matrix for the kth subject d k = random coefficients for the kth subject; d k contains increments to population intercepts and slopes V k = vector of random measurement errors for the kth subject.
The fixed-effect design matrix X k and fixed-effect parameters β in the mixed model are similar to the design matrix and the regression parameters in a typical multiple regression, analysis of variance (ANOVA), or analysis of covariance (ANCOVA) model, where E(Y k ) = X k β. Thus, an element of β may represent the "slope" of a regression surface with respect to a covariate, to a treatment effect, or to a similar quantity.
The random-effects design matrix Z k and the subject-specific random effects d k represent random deviations from E(Y k ) = X k β that are associated with the kth subject. V k is a vector of random deviations, 
Analysis
Analyzing missing data requires making assumptions about the missing values as being either ignorable or nonignorable. For simplicity, we assume that all the missing values are ignorable in our simulation. Our simulation is based on a design that compares differences in lumber spine bone mineral density (BMD) values between two groups in a multicenter randomized clinical trial. We adopted this approach because the original drug trial design compared postmenopausal, non-osteoporotic women who received Drug A as treatment with similar women who received a placebo. For confidentiality reasons, we are not specifying the drug name or the manufacturer.
To determine the number of subjects required, we assumed that the variance-covariance matrices would be the same for both the drug A and the placebo groups of subjects. We also assumed that each subject was scheduled to make five visits over a 15-month period. Further, we assumed (a) that the baseline mean value of bone loss is 0.715 gHA/cm 2 for both treatment and placebo groups and (b) that at the end of the five visits, the placebo group's mean value for bone loss will have been the same (0.715) and the treatment group's mean value for bone loss will have increased to 0.745. In other words, we assumed that the difference in mean lumber spine BMD loss will be 0.030 at the end of five visits. We estimated that 138 subjects in each group would allow us to detect a lumber spine BMD difference of 0.03 with 90 percent power at 5 percent significance level for a one-sided test.
Our study goal is to simulate a real clinical trial scenario in which missing data occur. For these purposes, data are missing because women in both the treatment and the placebo groups randomly missed some visits at which data would otherwise have been collected. The pattern of the missing data is created in the simulation following the key assumptions listed below:
1. Women are enrolled into five study centers.
2. Each center randomly assigns subjects to the treatment and placebo arms in a 1:1 ratio.
3. On average, each study center enrolls 55 patients, with a range of variation between 25 and 75 patients.
4. Each randomized patient has five visits over a 15-month period.
5. Twenty percent of the subjects drop out of the trial after the first visit.
6. Of the remaining four visits, between 5 percent and 50 percent are missed by the women remaining in the study.
We assigned missing visits randomly to each subject. We then simulated data from a multivariate normal distribution in which the variances of lumber spine BMD value is 0.005 for both groups for all visits and the lumber spine BMD values are positively correlated within each patient with a correlation coefficient of 0.7.
Initially, each simulated dataset contained 276 subjects-138 for the placebo group and 138 for the treatment group-with five visits by each subject. We generated dropouts, namely, the random 20 percent of women who dropped out after the first visit. We then generated missing data as the percentages of missed visits, ranging from 0 percent (i.e., no missed visits) to 50 percent (half of the visits were missed); we did this in 5-percentage-point increments (0 percent, 5 percent, …, 45 percent, 50 percent) for the subjects who had not dropped out of the trial after the first visit. We used a mixed model with an unstructured covariance matrix to compare the mean differences in lumbar spine BMD at the fifth visit between the drug and the placebo groups, for the original datasets with missing values and for all the other versions of imputed datasets. The fixed-effect design matrix includes drug groups (drug A and placebo), centers (1 to 5), and visits (1 to 5). The random-effects design matrix includes a random intercept and a slope for subjects.
We repeated this simulation process 5,000 times and recorded the test results with p values for all four analysis methods during each simulation run. We used SAS 9. 2 9 to simulate and analyze the data.
Results
In general, as Figures 1 though 4 We do not have adequate samples to detect small differences because we calculated our sample size to detect a difference of 0.3. On the other hand, if the differences between two groups are greater than 0.03, then we have enough power to detect the differences. In summary, mixed model analysis without any ad hoc imputation always provides equal or more power than does analysis using mixed models with missing values imputed by LOCF, BVR, or WVR ad hoc imputation methods.
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